Loading
The 2023 report of the international expert panel that meets every two years to vote on how early breast cancer should be treated, this time stressing multidisciplinary decisions and the right intensity and duration of treatment.
Report of the 18th St Gallen International Breast Cancer Conference, held in March 2023 in Vienna, by Curigliano, Burstein, Gnant, Loibl and colleagues. The panel assessed new findings for local and systemic therapy of early breast cancer with a focus on multimodal options, emphasised multidisciplinary discussion of the clinical benefit of interventions as integral to a plan with the right degree of intensity and duration, concentrated on ductal (no special type) and lobular histologies, and framed its opinions as interpretations of data shaped by practice environments, patient factors and reimbursement and access constraints worldwide, while advocating participation in well-designed clinical studies.
St Gallen is where de-escalation questions in triple-negative disease (who needs the full KEYNOTE-522 regimen, who can skip adjuvant pembrolizumab) are first put to a vote; the 2023 panel framed intensity and duration as the central problem.
Shares Giuseppe Curigliano, Sibylle Loibl, De-escalation, escalation and response-adapted therapy, Annals of Oncology and the tag tnbc-evidence.
Shares Sibylle Loibl, Annals of Oncology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Giuseppe Curigliano, Annals of Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease, De-escalation, escalation and response-adapted therapy, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Give exceptional responders less: pembrolizumab omission after complete response, anthracycline-free regimens and chemotherapy omission in lymphocyte-rich stage I disease, HER2-positive breast cancer, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Annals of Oncology, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag tnbc-evidence.